• DNase I (RNase-free) for Cancer RNA Workflows

  2026-08-11

  Learn how to use DNase I (RNase-free) to improve RNA extraction, RT-qPCR, in vitro transcription, and chromatin workflows without compromising RNA integrity. The workflow also translates findings on CAF-derived lactate and oxaliplatin resistance into practical nucleic-acid quality controls.

• Thiothixene Drives Continual Macrophage Efferocytosis

  2026-08-10

  A 2025 Science Signaling study identifies Thiothixene as a repurposing candidate that enhances macrophage clearance of apoptotic and lipid-laden cells, including repeated rounds of efferocytosis. The work connects this activity to Stra6L-dependent vitamin A signaling and Arginase 1 induction while showing that dopamine suppresses efferocytosis and is only partly counteracted by the drug.

• Ziprasidone Augmentation in Anxious Depression

  2026-08-09

  This post-hoc moderator analysis examined whether baseline anxious depression changed the response to ziprasidone added to escitalopram in patients with major depressive disorder. Ziprasidone augmentation showed comparable antidepressant effects across anxiety subgroups, while the apparent anxiety benefit was not clinically meaningful in patients with anxious depression.

• Hepatic sEH–Nrf2 Axis in Osteoporosis

  2026-08-08

  A recent study identifies a liver–bone axis in which hepatic soluble epoxide hydrolase alters circulating epoxyeicosatrienoic acid metabolites, suppresses Nrf2-ARE signaling, and promotes osteoclast differentiation. Its combination of clinical samples, an ovariectomy mouse model, liver-specific manipulation, metabolite analysis, and transcriptomics provides a mechanistic framework for studying redox imbalance in osteoporosis.

• Minoxidil sulphate for Reliable Cell Assays

  2026-08-07

  A scenario-based guide to using Minoxidil sulphate (SKU C6513) in cell viability, proliferation, cytotoxicity, vascular biology, and hair follicle workflows. It connects material quality, solvent handling, potassium-channel biology, and assay interpretation to practical laboratory decisions.

• Machine Learning Advances Lipid Nanoparticle Design for mRNA

  2026-08-07

  This study pioneers a machine learning approach to predict and optimize lipid nanoparticle (LNP) formulations for mRNA vaccine delivery. The integration of a LightGBM algorithm with molecular modeling enables rapid identification of effective ionizable lipid substructures, improving efficiency and reducing experimental burden.

• NU6300 Inhibits Gasdermin D via Cysteine-191 Covalent Modifi

  2026-08-06

  Jiang et al. identify NU6300 as a covalent gasdermin D (GSDMD) inhibitor, targeting cysteine-191 to block both cleavage and palmitoylation events central to pyroptosis. This work clarifies feedback mechanisms in inflammasome signaling and provides a methodological foundation for developing new GSDMD-targeted therapies in inflammatory disease models.

• Vemurafenib (PLX4032): Advancing Melanoma Resistance Researc

  2026-08-06

  This thought-leadership article explores how Vemurafenib (PLX4032) empowers translational research into melanoma cell proliferation inhibition and resistance network mapping. Integrating recent multi-omics insights—especially those revealing ARID1A-dependent resistance mechanisms—this piece bridges deep mechanistic understanding with actionable, strategy-driven guidance. By dissecting the MAPK/ERK pathway, evaluating resistance adaptation, and contextualizing APExBIO’s Vemurafenib within the evolving landscape of cancer biology, we deliver a forward-looking roadmap for researchers seeking to outpace therapeutic resistance in metastatic melanoma.

• E-64 L-trans-epoxysuccinyl Peptide: Precision in Cysteine Pr

  2026-08-05

  E-64, a potent L-trans-epoxysuccinyl peptide, enables irreversible and highly selective cysteine protease inhibition—crucial for dissecting proteolytic pathways in mechanistic and translational research. This article details actionable workflows, troubleshooting strategies, and novel applications, empowering researchers to harness E-64 for reproducible, high-impact experiments.

• 0.4% Trypan Blue Solution: Technical Guide for Cell Viabilit

  2026-08-05

  0.4% Trypan Blue Solution provides a robust method for distinguishing viable from non-viable cells during cell viability measurement, cell counting, and cytotoxicity assays. Its exclusion-based staining enables fast, direct assessment of culture health in research workflows, but it is not intended for diagnostic or clinical use.

• ZK53: Targeted ClpP Activation for Translational Oncology

  2026-08-04

  Explore how ZK53, a selective human mitochondrial serine protease ClpP activator, is redefining mitochondrial dysfunction modeling and anti-cancer strategy in translational research. By integrating recent mechanistic insights and protocol guidance, this article offers strategic direction for researchers navigating the evolving landscape of mitochondrial-targeted oncology.

• Circulating Polyploid Giant Cancer Macrophages as Prognostic

  2026-08-04

  This study establishes phagocytic polyploid giant cancer macrophages (CAMLs) in blood as robust indicators of disease progression across multiple solid tumors. By characterizing CAMLs’ unique cellular properties and their correlation with metastatic niche formation, the research opens new avenues for early cancer monitoring and mechanistic investigation.

• Actinomycin D (SKU A4448): Reliable Solutions for Molecular

  2026-08-03

  This scenario-driven article addresses key workflow and interpretation challenges in cell viability and mRNA stability assays, demonstrating how Actinomycin D (SKU A4448) supports reproducibility and data reliability in cancer research and transcriptional stress models. We explore real laboratory situations, evidence-backed optimizations, and vendor selection with a focus on APExBIO's Actinomycin D.

• EZ Cap™ Firefly Luciferase mRNA (5-moUTP): Mechanistic Insig

  2026-08-03

  Explore the advanced design of EZ Cap™ Firefly Luciferase mRNA (5-moUTP), a 5-moUTP modified mRNA enabling high-fidelity bioluminescent reporting. This comprehensive review reveals mechanistic breakthroughs and practical protocol guidance, distinguishing it from standard summaries.

• Olive Biophenols Attenuate Amyloid Pathology in Alzheimer’s

  2026-08-02

  This study demonstrates that olive-derived biophenols—particularly oleuropein, verbascoside, and rutin—effectively inhibit amyloid beta aggregation and reduce neurotoxicity in both cellular and transgenic mouse models of Alzheimer’s disease. These findings highlight the potential of natural compounds in modifying key pathological processes in AD, suggesting promising avenues for further mechanistic and translational research.

16170 records 2/1078 page Previous Next 12345 下5页 Last page